In a groundbreaking advancement at the intersection of synthetic biology and gastrointestinal research, Dr. Ilana Kolodkin-Gal of the Scojen Institute for Synthetic Biology has been awarded a prestigious research grant through the BSF-NSF joint program. This collaboration, bridging Israeli and American scientific communities via the U.S.-Israel Binational Science Foundation and the U.S. National Science Foundation, seeks to foster pioneering research initiatives. Dr. Kolodkin-Gal’s project focuses on elucidating the mechanisms by which invasive and pathogenic strains of intestinal bacteria compromise the structural and functional integrity of the gut barrier—an area that holds immense significance for understanding inflammatory bowel diseases (IBD), including Crohn’s disease.
The intestinal barrier functions as a critical interface between the external environment and the host’s internal milieu, primarily maintained by a complex polysaccharide layer called mucin. Mucin is integral to protecting the gut lining from bacterial invasion and other environmental insults. Disruptions to this barrier are increasingly implicated in the pathogenesis of IBD, where an aberrant immune response to altered microbial communities accelerates chronic inflammation. Dr. Kolodkin-Gal’s laboratory has previously demonstrated that subtle, specific changes in the chemical composition and physical properties of mucin serve as biomarkers of microbial interference, heralding the early stages of intestinal inflammation and disease progression.
What distinguishes this research is its innovative methodological approach, which ambitiously seeks to engineer a “mucin-on-a-chip”—a microfluidic platform that recapitulates the biochemical physiology and mechanical dynamics of the intestinal mucosal surface. This organ-on-a-chip technology is designed to model the complex microenvironment of the gastrointestinal tract with unprecedented precision, allowing researchers to observe in real-time how bacterial strains disrupt mucosal integrity. This synthetic biology tool harbors immense potential to unravel multifaceted host-microbe interactions that are otherwise obscured in traditional in vivo or ex vivo studies, enabling mechanistic insights at molecular and cellular levels.
The development of this mucin-on-a-chip is poised to represent a conceptual paradigm shift in the study and treatment of chronic inflammatory gastrointestinal conditions. Rather than merely managing symptoms pharmacologically, this platform could enable the design of targeted therapeutic interventions that modulate specific bacterial communities implicated in disease pathology. The hypothesis that gut bacterial consortia act as drivers rather than mere passengers in chronic inflammation challenges conventional thinking and opens avenues for microbiome-based precision medicine, where sculpting microbial populations could restore barrier function and immune homeostasis.
Further amplifying the potential impact of the project, Dr. Kolodkin-Gal’s team is collaborating with distinguished experts in complementary fields. Co-investigators Prof. Hadar Ben-Yoav from Ben-Gurion University and Prof. Thomas Wood of Penn State University bring critical expertise in mucosal biology and microbial ecology, respectively. This multidisciplinary partnership ensures a robust integration of synthetic biology, bioengineering, microbiology, and clinical relevance, which is essential for translating laboratory findings into therapeutic innovation.
Inflammatory bowel disease is a notoriously complex condition characterized by an interplay between genetic predisposition, immune dysregulation, and environmental factors, including the microbiome. The precise roles of invading bacterial strains have eluded definitive characterization due to the complexity of microbial interactions and the difficulty in modeling dynamic mucosal environments. By employing the mucin-on-a-chip, the research team anticipates delineating how pathogen-associated molecular patterns and bacterial secreted metabolites alter mucin chemistry and subsequently, barrier permeability and immune activation.
This approach represents a leap forward beyond conventional in vitro cell cultures or animal models, which lack the physiological and mechanical fidelity of the human gastrointestinal tract. The microfluidic device will incorporate controlled flows, mucin layering, and bacterial colonization patterns to simulate the realistic spatiotemporal heterogeneity of the intestinal interface. Monitoring how invasive bacteria modify mucin’s glycosylation patterns and viscosity, and how these alterations translate to barrier dysfunction, will generate critical data on the initial steps of mucosal breach and disease amplification.
Moreover, the insights gained from this platform are expected to facilitate rapid screening of potential drug candidates or probiotic formulations capable of restoring mucin integrity or selectively inhibiting pathogenic strains. This could revolutionize therapeutic paradigms for diseases like Crohn’s, where current treatments often involve systemic immunosuppression with substantial side effects. A precision-targeted microbial approach could offer safer, personalized interventions that address disease etiology at the microbial-host interface.
The joint BSF-NSF grant underpinning this research underscores the global importance of understanding IBD pathophysiology, and exemplifies the power of international collaboration in solving complex biomedical problems. It also highlights the growing relevance of synthetic biology tools in biomedical engineering—tools that transform biological phenomena into engineerable systems with diagnostic and therapeutic potential.
As research proceeds, the generation of the mucin-on-a-chip and subsequent experimental validation will serve not only as a model for IBD but may also be adapted to study other mucosal diseases where barrier integrity is compromised, including colorectal cancer and infectious enteropathies. This versatility makes the project a beacon of innovation with broad translational potential.
In summary, Dr. Ilana Kolodkin-Gal’s award-winning research marks a significant milestone towards understanding and combating inflammatory bowel diseases at a molecular and microbial level. By pioneering a mucin-on-a-chip platform, the study promises to unravel the intricate dialogue between invasive bacteria and the intestinal mucosal barrier, potentially transforming our approach to treating chronic gastrointestinal inflammation through precision synthetic biology and microbiome engineering.
Subject of Research: Investigating bacterial disruption of intestinal mucin integrity in inflammatory bowel disease through innovative mucin-on-a-chip technology.
Article Title: [Not provided]
News Publication Date: [Not provided]
Web References: [Not provided]
References: [Not provided]
Image Credits: [Not provided]
Keywords: Synthetic biology, inflammatory bowel disease, mucin, intestinal barrier, mucin-on-a-chip, Crohn’s disease, gastrointestinal microbiome, bioengineering, microbial interference, chronic inflammation
